The SynchroMed II Implantable and SynchroMed EL Implantable infusion pumps may stall intermittently or completely halt, which can interrupt medications being delivered.
The only drugs approved for use with these pumps are morphine, baclofen, ziconotide, floxuridine and methotrexate. Drugs not approved increase the failure rate of the device from 2.4 percent to 7 percent.
More Articles on Devices:
Omeros Shares Drop 9% After Knee Surgery Clinical Trial Results Released
Aspen Valley Hospital Acquires MAKOplasty Robotic System
Wood May be Suitable Bone Replacement in Orthopedic Implants
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.